Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus Nilotinib in Chronic Phase CML Resistant to Imatinib
2015-001318-92Phase 3Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Ponatinib with Nilotinib (2 arms). Primary endpoint: Major molecular response by 12 months. Started Oct 2015; status: completed.
02
Drugs
ponatinibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2015-001318-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001318-92.